A Multicenter Non-interventional Single-arm Retrospective-prospective Observational Study in Therapeutic Approaches on AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) in Real Clinical Practice in Russia
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (≥18 years) with a confirmed diagnosis of AQP4-IgG positive NMOSD following the 2015 IPND criteria;
• Provision of signed and dated written informed consent.
Locations
Other Locations
Russian Federation
Research Site
RECRUITING
Novosibirsk
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-12-23
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca